Abstract: The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.
Type:
Application
Filed:
July 6, 2023
Publication date:
November 2, 2023
Applicant:
I.D.BIO
Inventors:
Yeo-Jeong CHOI, Su-Jin PARK, Young-Il KIM, Min-Ah YU
Abstract: The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.
Type:
Grant
Filed:
April 23, 2019
Date of Patent:
August 29, 2023
Assignee:
I.D.BIO.
Inventors:
Yeo-Jeong Choi, Su-Jin Park, Young-Il Kim, Min-Ah Yu
Abstract: The present disclosure relates to a novel recombinant influenza virus, in which an interferon-beta gene, which is a foreign gene associated with an antiviral action, is introduced to an NS1 gene which is an influenza virus gene that is expressed first in the host to suppress the host immune system when infected with the influenza virus, and, in contrast to existing research, the interferon-beta is separated from the NS1 protein to carry out an intrinsic function of interferon-beta of inducing an antiviral action.
Abstract: The present invention relates to a novel genotype of severe fever with thrombocytopenia syndrome viruses and use thereof as an immunogenic composition. The severe fever with thrombocytopenia syndrome viruses of the present invention are genetically different from conventional severe fever with thrombocytopenia syndrome viruses and are novel viruses taxonomically belonging to three sub-groups of genotype B. In view of the vaccine property that specific genotype viruses alone show only limited protective potential, the novel viruses of the present invention may be advantageously used as a vaccine having excellent cross-immunogenicity for SFTSV.
Type:
Application
Filed:
April 23, 2019
Publication date:
April 29, 2021
Applicant:
I.D.BIO.
Inventors:
Yeo-Jeong CHOI, Su-Jin PARK, Young-II KIM, Min-Ah YU